Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors

X
Trial Profile

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TOS-358 (Primary)
  • Indications Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Totus Medicines
  • Most Recent Events

    • 19 Apr 2023 Trial design presented at the 114th Annual Meeting of the American Association for Cancer Research
    • 13 Apr 2023 According to a Totus Medicines media release, the first patient has been dosed in the study.
    • 10 Apr 2023 According to a Totus Medicines media release, company will be presenting poster presentation for this trial at the American Association for Cancer Research (AACR) Annual Meeting, Abstract: CT249, on Tuesday April 18 at 1:30 PM - 5:00 PM ET.full abstracts will be available on the AACR and Totus Website.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top